Research Journal of Pharmacy and Technology

Acinetobacter Species are ubiquitous in the environment, and have emerged as important nosocomial pathogens. They are resistant to many antibiotic groups, especially beta lactams which is the most clinically-important group. However, There is a poor knowledge about Acinetobacter susceptibility profile in Syria.

To detect distribution of Acinetobacter in different sections of involved hospital and its susceptibility profile to beta-lactams.

88 Acinetobacter samples obtained through 24 months from different departments of Al-Assad University Hospital, Latakia-Syria. Species was identified using api 20E and api 20NE (bioMérieux-France) and susceptibility profile for beta-lactams was detected using E-Test (bioMérieux-France) Results: The prevalence of Acinetobacter has reduced from 3.74% in the first year (2015) to 3.06% in the second year (2016), but the resistance to antibiotics used in the study has increased(except Azetreonam). The resistance rates were 11.4% for Ampicillin-Sulbactam, 78.4% for Ticarcillin-Clavulanic acid, 90.9% for Cefotaxime, 43.2% for Cefepime, 48.9% for Imipenem, 40.9% for Meropenem, and 44.3% for Azetreonam.

Acinetobacter develops resistance for beta-lactams rapidly. Ampicillin-Sulbactam is the drug of choice for Acinetobacter infections in Syria.